PI4KB: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: PI4KB

NCBI ID: G5298

PI4KB

PI4KB: A Promising Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The development of new pain treatments is crucial for improving the quality of life and reducing disability. One promising target for pain management is PI4KB, a protein kinase that plays a crucial role in the regulation of membrane phospholipids, including phosphatidylinositol (PIP). In this article, we will discuss PI4KB as a drug target and biomarker for chronic pain.

Background

PI4KB, also known as catalytic PI4KB or PIP4KB, is a protein kinase that is expressed in various tissues, including neurons, endothelial cells, and immune cells. It is a key regulator of membrane phospholipids, including PIP, which is a major component of cell membranes. PI4KB catalyzes the conversion of PIP into diacylglycerol (DAG), which is a key signaling molecule in various cellular processes, including intracellular signaling, cell signaling, and inflammation [1,2].

During pain perception, PI4KB is involved in the regulation of pain signaling pathways, including the production of neuropeptides, which are involved in pain modulation. For instance, PI4KB has been shown to play a role in the regulation of pain modulation by endogenous opioids, such as endocannabinoids and anandamide [3,4].

In addition to its role in pain modulation, PI4KB is also a potential drug target for various diseases, including chronic pain. The inhibition of PI4KB has been shown to be effective in treating chronic pain models, including neuropathic pain, pain-related neuroinflammation, and chronic pain models caused by various other mechanisms, such as thermal or mechanical pain [5,6].

As a biomarker, PI4KB has also been shown to be involved in the diagnosis and monitoring of chronic pain. The levels of PI4KB have been shown to be elevated in individuals with chronic pain, and reducing PI4KB levels has been shown to be effective in reducing chronic pain symptoms [7,8].

Targeting PI4KB

Several approaches have been proposed to target PI4KB and treat chronic pain. Here are some of the most promising approaches:

1. Small Molecule inhibitors

Small molecules have been widely used to target PI4KB and treat chronic pain. One of the most promising classes of small molecules is the PI4KB inhibitors, which include inhibitors of the PI4KB catalytic activity and inhibitors of PI4KB-associated signaling pathways. These inhibitors have been shown to be effective in treating various chronic pain models, including neuropathic pain and chronic pain caused by mechanical or thermal stimulation [9,10].

2. RNA-based therapeutics

RNA-based therapeutics have also shown promise in targeting PI4KB and treating chronic pain. One approach is to use small interfering RNA (siRNA) to knockdown PI4KB levels in target cells. siRNA-mediated knockdown of PI4KB has been shown to be effective in reducing pain symptoms in various pain models [11,12].

3. Peptide-based therapeutics

Peptide-based therapeutics have also shown promise in targeting PI4KB and treating chronic pain. One approach is to use antibodies to target PI4KB and enhance the activity of existing pain modulatory pathways. Monoclonal antibodies (mAbs) targeting PI4KB have been shown to be effective in reducing pain symptoms in various pain models [13,14].

4. Targeted therapies

Another approach to targeting PI4KB and treating chronic pain is to use targeted therapies, such as small molecules or antibodies that target specific

Protein Name: Phosphatidylinositol 4-kinase Beta

Functions: Phosphorylates phosphatidylinositol (PI) in the first committed step in the production of the second messenger inositol-1,4,5,-trisphosphate (PIP). May regulate Golgi disintegration/reorganization during mitosis, possibly via its phosphorylation. Involved in Golgi-to-plasma membrane trafficking (By similarity)

The "PI4KB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PI4KB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets